Parabolas of medication use and discontinuation after myocardial infarction - Are we closing the treatment gap?

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 7, 2007, Pages 773-785

  Hudson, Marie ^a   Richard, Hugues ^a   Pilote, Louise ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Discontinuation; Evidence based medications; Myocardial infarction; Population study; Treatment gap

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METOPROLOL; NITRATE; RAMIPRIL; SOTALOL; TICLOPIDINE; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DATA BASE; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; ELDERLY CARE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; DATABASES, FACTUAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS;

EID: 34547533955     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1414     Document Type: Article

References (31)

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article - a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the management of patients with unstable angina). Circulation 2002; 106(14): 1893-1900.
2. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88(3): 229-233.
3. Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf 2004; 13(11): 761-766.
4. Blackburn DE, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005; 25(8): 1035-1043.
5. Tran CTT, Laupacis A, Mamdani MM, Tu JV. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Amer Heart J 2004; 148(5): 834-841.
6. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147-1152.
7. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Amer J Med 2004; 117(2): 73-81.
8. Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 2005; 32(8): 1589-1593.
9. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141(2): 102-112.
10. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Amer J Epidemiol 2005; 162(10): 1016-1023.
11. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiologic research - the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol 19951 48(8): 999-1009.
12. Hudson M, Rahme E, Richard H, Pilote L. Comparison of measures of medication persistency using a prescription drug database. Amer Heart J 2007; 153(1): 59-65.
13. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11(7): 453-460.
14. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort stud. Can J Cardiol 2005; 21(6): 485-488.
15. Jackevicius CA, Mamdami M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Jama-J Am Med Assn 2002; 288(4): 462-467.
16. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Amer Heart J 2003; 145(3): 438-444.
17. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients - the treatment-risk paradox. Jama-J Am Med Assn 2004; 291(15): 1864-1870.
18. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction - The guidelines applied in practice (GAP) initiative. Jama-J Am Med Assn 2002; 287(10): 1269-1276.
19. Birkhead JS, Walker L, Pearson M, Weston C, Cunningham AD, Rickards AF. Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP). Heart 2004; 90(9): 1004-1009.
20. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of stalin therapy in elderly patients. Jama-J Am Med Assn 2002; 288(4): 455-461.
21. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications - A cross-national study. Jama-J Am Med Assn 19981 279(18): 1458-1462.
22. Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Amer J Cardiol 2004; 94(1): 20-24.
23. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history - a life course analysis of the original Framingham Heart Study Cohort. Eur Heart J 2002; 23(6): 458-466.
24. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366(9499): 1773-1783.
25. Wahl C, Gregoire JP, Teo K, et al. Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthc Q 2005; 8(1): 65-70.
26. World Health Organization. Adherence to Long-term Therapies: Evidence for Action. Geneva, World Health Organisation: 2003.
27. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 2004; 21(12): 793-811.
28. Sud A, Kline-Rogers EM, Eagle. KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005; 39(11): 1792-1797.
29. Bane C, Hughes CM, McElnay JC. The impact of depressive symptoms and psychosocial factors on medication adherence in cardiovascular disease. Patient Educ Couns 2006; 60(2): 187-193.
30. Jones G. Prescribing and taking medications. BMJ 2003; 327: 819.
31. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005; 4: CD000011.